Novo Nordisk's rendering of its Kalundborg, Denmark site, showing expansion of production facilities to be completed in 2029 (Credit: Novo Nordisk)

No­vo in­vests $6B+ to ex­pand man­u­fac­tur­ing fa­cil­i­ties as de­mand for We­govy sky­rock­ets

No­vo Nordisk is in­vest­ing more than DKK 42 bil­lion ($6 bil­lion) to ex­pand its ex­ist­ing man­u­fac­tur­ing fa­cil­i­ties in Den­mark, most­ly to in­crease its ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (API) ca­pac­i­ty, the com­pa­ny an­nounced Fri­day.

The fa­cil­i­ties in Kalund­borg, Den­mark, will be able to man­u­fac­ture mul­ti­ple prod­ucts, in­clud­ing GLP-1s, to “meet fu­ture mar­ket de­mands” as the de­mand for its weight loss prod­uct, We­govy, con­tin­ues to soar. This in­vest­ment will al­so boost pack­ag­ing ca­pac­i­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.